GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: Asut® | Embodiment 1 [US11111236B2] | example 19 [US20200054594A1] | SHR-8554 | SHR8554
                                 
                                                         
                            
                            
                            
                                 
                                
                                tegileridine is an approved drug (China (2024)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Tegileridine (SHR8554) is an intravenously bioactive μ-opioid receptor agonist. It selectively activates the G protein-coupled pathway [2] and only weakly activates β-arrestin 2 recruitment. G protein-coupling bias is predicted to limit side effects such as respiratory depression and gastrointestinal inhibition.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Dhillon S. (2024)
                                         Tegileridine: First Approval. Drugs, 84 (6): 717-720. [PMID:38771484]  | 
                                                                
| 
                                                                         2. Shi R, Chai Y, Feng H, Xie L, Zhang L, Zhong T, Chen J, Yan P, Zhu B, Zhao J et al.. (2023)
                                         Study of the mass balance, biotransformation and safety of [14C]SHR8554, a novel μ-opioid receptor injection, in healthy Chinese subjects. Front Pharmacol, 14: 1231102. [PMID:37781692]  | 
                                                                
| 
                                                                         3. Zhao X, Yuan L, Gong Z, Li M, Yuan Y, Geng J. (2025)
                                         New drugs approved by the NMPA in 2024: Synthesis and clinical applications. Eur J Med Chem, 291: 117643. [PMID:40262297]  |